Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date

Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date

Vincent Chau, Marijo Bilusic Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USACorrespondence: Marijo Bilusic Tel +1-301-765-4457Fax +1-240-541-4548Email marijo.bilusic@nih.govAbstract: Over the last 18 mon...

Full description

Bibliographic Details
Main Authors: Chau V, Bilusic M
Format: Article
Language:English
Published: Dove Medical Press 2020-08-01
Series:Cancer Management and Research
Subjects:
pembrolizumab
axitinib
renal cell carcinoma
Online Access:https://www.dovepress.com/pembrolizumab-in-combination-with-axitinib-as-first-line-treatment-for-peer-reviewed-article-CMAR

Internet

https://www.dovepress.com/pembrolizumab-in-combination-with-axitinib-as-first-line-treatment-for-peer-reviewed-article-CMAR

Similar Items